Side-by-side · Research reference
5-Amino-1MQvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BFDA-ApprovedReviewed13/41 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
5-Amino-1MQ
PT-141
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
PT-141
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily, fasted
PRN, max 8 doses / month
Lower / starter dose
50 mg / day
1 mg (off-label)
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
8–12 weeks per cycle
PRN; reassess if no benefit after 8 doses
Form
Oral capsule
—
Timing
Morning fasted preferred
≥45 min before sexual activity
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
04Side Effects & Safety
Parameter
5-Amino-1MQ
PT-141
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Contraindicated
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
5-Amino-1MQ
PT-141
1. Form
Oral capsule. No injection.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Administration
Take with water, fasted preferred.
SQ — abdomen or thigh.
3. Timing
Morning fasted.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Room temp ≤25 °C, dry place.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Caveat
Monitor B-vitamin status with chronic use.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.